Skip to main content

Table 2 Efficacy at weeks 2, 6, and 12

From: Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial

Activity index Time Mean ± SD change from the baseline
Kunxian, n = 35 Placebo, n = 33
BASDAI (0–10), mean (±SD) Week 2 -1.46 ± 1.61 -0.91 ± 1.31
  Week 6 -1.98 ± 1.48a -0.10 ± 1.13
  Week 12 -1.68 ± 1.70 -1.11 ± 1.17
BASFI (0–10), mean (±SD) Week 2 -0.52 ± 1.17 -0.15 ± 1.32
  Week 6 -0.88 ± 1.18c -0.28 ± 1.27
  Week 12 -0.75 ± 2.26 -0.01 ± 1.59
ASDAS-CRP, mean (±SD) Week 2 -0.84 ± 0.91b -0.05 ± 0.98
  Week 6 -1.25 ± 0.95a -0.06 ± 0.70
  Week 12 -1.08 ± 1.03b -0.11 ± 1.79
ESR (mm/h), mean (±SD) Week 2 -11.26 ± 16.38c 0.15 ± 9.48
  Week 6 -16.26 ± 18.63b 0.71 ± 16.76
  Week 12 -14.51 ± 22.65c 0.09 ± 16.50
CRP (ref 6 mg/l), mean (±SD) Week 2 -16.49 ± 21.12b 0.37 ± 16.55
  Week 6 -20.66 ± 23.71b 1.07 ± 20.20
  Week12 -18.50 ± 26.18c 0.76 ± 16.67
Level of morning stiffness, 0–10 cm VAS Week2 -2.56 ± 2.81c -0.88 ± 1.37
  Week6 -2.10 ± 2.39c -0.78 ± 2.38
  Week 12 -2.53 ± 2.60c -1.34 ± 1.67
Global assessment, 0–10 cm VAS Week 2 -1.29 ± 1.94 -0.54 ± 1.30
  Week 6 -1.99 ± 2.10c -0.81 ± 1.31
  Week 12 -1.69 ± 2.30 -0.85 ± 1.55
Total back pain, 0–10 cm VAS Week 2 -1.22 ± 1.99 -0.45 ± 1.60
  Week 6 -1.97 ± 2.08c --0.81 ± 1.98
  Week 12 -1.94 ± 2.17c -0.77 ± 1.57
Swollen joints, range 0–44 Week 2 -0.14 ± 0.42 0.14 ± 0.85
  Week 6 -0.16 ± 0.5 -0.05 ± 0.34
  Week 12 0 ± 0.82 -0.06 ± 0.34
Tender joints, range 0–44 Week 2 -1.19 ± 2.77 -0.35 ± 0.73
  Week 6 -2.38 ± 3.66c -0.26 ± 1.24
  Week 12 -2.89 ± 3.43c -0.36 ± 1.32
BASMI (0–10), mean (±SD) Week 2 -0.32 ± 0.94 -0.32 ± 0.97
  Week 6 -0.49 ± 1.10 -0.14 ± 0.98
  Week 12 -0.24 ± 1.09 -0.21 ± 0.95
  1. aCompared with placebo group. p< 0.0001
  2. bCompared with placebo group. p< 0.001
  3. cCompared with placebo group. p < 0.05